177660-92-3

Basic information

• Product Name: Benzenesulfonamide, 4-[2-(5-methyl-3-pyridinyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]-
• CAS NO: 177660-92-3
• Molecular Formula: C16H13F3N4O2S
• Molecular Weight: 382.366
• Mol File: 177660-92-3.mol
• Article Data: 22

Chemical Properties

• CAS DataBase Reference: Benzenesulfonamide, 4-[2-(5-methyl-3-pyridinyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenesulfonamide, 4-[2-(5-methyl-3-pyridinyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]-(177660-92-3)
• EPA Substance Registry System: Benzenesulfonamide, 4-[2-(5-methyl-3-pyridinyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]-(177660-92-3)

Safety Data

• Hazardous Substances Data: 177660-92-3(Hazardous Substances Data)

Upstream product

• 177660-88-7 3-methyl-5-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine 
• 104-96-1 4-methylsulfanylaniline 
• 42885-14-3 5-cyano-3-methylpyridine 
• 70-57-5 5-methylpyridinylcarboxamide 

Downstream Products

• 198470-73-4 N-[[4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]butanamide 
• 198470-67-6 N-[[4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]acetamide 

Relevant articles and documents

COMBINATION OF A SELECTIVE NMDA NR2B ANTAGONIST AND A COX-2 INHIBITOR

The present invention provides a combination of a selective NMDA NR2B antagonist and a COX-2 inhibitor for the treatment or prevention of pain or nociception.

Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor

This invention relates to the use of a tocolytic agent or agents in combination with selective cyclooxygenase-2 inhibitors of Formula (II) or a pharmaceutically-acceptable salt or derivative thereof for preparing a medicament for maintaining circulation through fetal ductus arteriosus during treatment or prevention of preterm labor in a subject in need of such treatment or prevention.

Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor

The present invention provides a method for the treatment or prophylaxis of COX-2-mediated conditions in patients who are at risk of developing thromboembolic events which comprises administering to said patient a therapeutically or prophylactically effective amount of a COX-2 selective inhibitor and a cardiovascular protective amount of a thromboxane inhibitor, as well as compositions therefor.